Enzyme-encapsulating polymeric nanoparticles: A potential adjunctive therapy in Pseudomonas aeruginosa biofilm-associated infection treatment.

Pseudomonas aeruginosa is a pathogen known to be associated with a variety of diseases and conditions such as cystic fibrosis, chronic wound infections, and burn wound infections. A novel approach was developed to combat the problem of biofilm antibiotic tolerance by reverting biofilm bacteria back to the planktonic mode of growth. This reversion was achieved through the enzymatic depletion of available pyruvate using pyruvate dehydrogenase, which induced biofilm bacteria to disperse from the surface-associated mode of growth into the surrounding environment. However, direct use of the enzyme in clinical settings is not practical as the enzyme is susceptible to denaturation under various storage conditions. We hypothesize that by encapsulating pyruvate dehydrogenase into degradable, biocompatible poly(lactic-co-glycolic) acid nanoparticles, the activity of the enzyme can be extended to deplete available pyruvate and induce dispersion of mature Pseudomonas aeruginosa biofilms. Several particle formulations were attempted in order to permit the use of the smallest dose of nanoparticles while maintaining pyruvate dehydrogenase activity for an extended time length. The nanoparticles synthesized using the optimal formulation showed an average size of 266.7 ± 1.8 nm. The encapsulation efficiency of pyruvate dehydrogenase was measured at 17.9 ± 1.4%. Most importantly, the optimal formulation dispersed biofilms and exhibited enzymatic activity after being stored at 37 °C for 6 days.